IFM Tre Inc is a spin-out of IFM Therapeutics Inc, an Abingworth portfolio company that was acquired by Bristol-Myers Squibb in 2017 for up to $2.3 billion. IFM Tre is developing a portfolio of NLRP3 antagonists for the treatment of serious inflammatory diseases. These small molecules have the potential to selectively block inappropriate responses of the innate immune system, with the first candidates expected to enter the clinic in 2019.

LocationBoston, Massachusetts
CEOGary Glick
PartnerVincent Miles